Zimmer Biomet Shares Jump 13%, Adding $2.5 Billion After Company Lifts 2026 Sales Forecast

Hips and surgical products offset weaker knees as the orthopedic implant maker raised its 2026 organic growth outlook to 3.0%-3.5%.

Share
Zimmer Biomet Shares Jump 13%, Adding $2.5 Billion After Company Lifts 2026 Sales Forecast

Zimmer Biomet, which makes knee and hip replacements and other orthopedic products, saw its shares jump 13.45% to $110.11 in Wednesday trading as of 9:56 a.m. ET after it raised its 2026 organic growth forecast to 3.0%-3.5%, from 2.25%-3.25%. The move added about $2.5 billion in market value and set a new 52-week high.

Hips Carry A Weak Knee Quarter

Hip sales rose 7.0%, while knees fell 2.6%, according to the company's third-quarter results. Sales in the quarter came to $2.063 billion.

Operating margin slipped to 14.9% from 17.6%. Adjusted earnings per share guidance now spans $8.50 to $8.60.

The CEO also pulled forward the launch of an autonomous knee robot, now targeted for early 2027.

A Biggest-In-275-Sessions Pop

The stock was on pace for its biggest one-day gain in at least 275 trading sessions, since Oct. 1, 2025. Its market value stood near $21 billion at that reading.

Before Wednesday, shares were up about 8% year to date as of Tuesday's close, trailing the S&P 500, which was up about 11% over the same span.

Zimmer sells to orthopedic surgeons, neurosurgeons, hospitals and surgery centers, and its ROSA Robot is part of its digital and robotic line. Its prior quarterly filing showed revenue of $2.2 billion, up 4.8% from a year earlier, with net income of $198.3 million.

The accelerated knee robot launch, now aimed at early 2027, is the company's answer to a knee business that is still shrinking.

Sources

More on Zimmer Biomet

All Zimmer Biomet (ZBH) coverage →